Prelude Therapeutics Inc Insider Trading Activity
Every SEC Form 4 insider transaction reported for Prelude Therapeutics Inc (PRLD), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are PRLD insiders buying or selling?
In the last 12 months, Prelude Therapeutics Inc insiders reported 2 open-market purchases ($25.0M) and 0 sales ($0) — net buying of $25.0M. Since September 2020, Trabud has recorded 57 Form 4 filings for PRLD: 29 buys ($113.6M) and 28 sells ($10.4M).
Source: SEC EDGAR Form 4
Key Statistics (September 2020 – Apr 23, 2026)
Total Form 4 filings
57
SEC EDGAR
Insider filers
14
Insider buys (29)
$113.6M
Insider sells (28)
$10.4M
Insider sentiment
Net buyingNet insider flow of $103.2M in net buying since September 2020, and $25.0M in net buying over the last 12 months.
Recent PRLD insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | David P Bonita | Director, 10% Owner | Purchase | 2.8M | $4.44 | $12.5M | SEC ↗ |
| Apr 23, 2026 | ORBIMED ADVISORS LLC | Director, 10% Owner | Purchase | 2.8M | $4.44 | $12.5M | SEC ↗ |
| Mar 27, 2025 | Andrew Combs | Chief Chemistry Officer | Purchase | 100.0K | $0.69 | $69.3K | SEC ↗ |
| Mar 27, 2025 | Vaddi Krishna | CEO | Purchase | 675.0K | $0.69 | $467.4K | SEC ↗ |
| Mar 24, 2025 | Vaddi Krishna | CEO | Purchase | 20.4K | $0.73 | $14.9K | SEC ↗ |
| Mar 18, 2025 | Vaddi Krishna | CEO | Purchase | 39.1K | $0.75 | $29.5K | SEC ↗ |
| Mar 14, 2025 | Vaddi Krishna | CEO | Purchase | 97.5K | $0.71 | $69.6K | SEC ↗ |
| Jan 3, 2025 | Vaddi Krishna | CEO | Purchase | 5.0K | $1.21 | $6.0K | SEC ↗ |
| Jan 2, 2025 | Vaddi Krishna | CEO | Purchase | 10.0K | $1.20 | $12.0K | SEC ↗ |
| Dec 26, 2024 | Andrew Combs | Chief Chemistry Officer | Purchase | 63.1K | $1.36 | $85.5K | SEC ↗ |
| Dec 20, 2024 | Bryant David Lim | CLO, Interim CFO, Corp Sec. | Purchase | 25.0K | $0.91 | $22.6K | SEC ↗ |
| Dec 20, 2024 | Vaddi Krishna | CEO | Purchase | 106.9K | $0.93 | $99.3K | SEC ↗ |
| May 26, 2023 | Vaddi Krishna | CEO | Purchase | 1.9K | $5.15 | $9.8K | SEC ↗ |
| May 25, 2023 | Bryant David Lim | Chief Legal Officer, Corp Sec. | Purchase | 2.4K | $5.39 | $12.9K | SEC ↗ |
| May 25, 2023 | Laurent Chardonnet | Chief Financial Officer | Purchase | 5.0K | $5.50 | $27.5K | SEC ↗ |
| May 25, 2023 | Vaddi Krishna | CEO | Purchase | 11.9K | $5.63 | $66.7K | SEC ↗ |
| May 24, 2023 | ORBIMED ADVISORS LLC | Director, 10% Owner | Purchase | 869.6K | $5.75 | $5.0M | SEC ↗ |
| May 24, 2023 | David P Bonita | Director, 10% Owner | Purchase | 869.6K | $5.75 | $5.0M | SEC ↗ |
| Apr 6, 2023 | Jane Huang | President, CMO | Sale | 13.3K | $6.12 | $81.3K | SEC ↗ |
| Dec 21, 2022 | Vaddi Krishna | CEO | Purchase | 19.2K | $5.13 | $98.4K | SEC ↗ |
| Dec 12, 2022 | Laurent Chardonnet | Chief Financial Officer | Purchase | 10.0K | $4.76 | $47.6K | SEC ↗ |
| Jun 1, 2022 | Laurent Chardonnet | Chief Financial Officer | Purchase | 10.0K | $4.23 | $42.3K | SEC ↗ |
| Dec 17, 2021 | Deborah Morosini | EVP, Chief of Clinical Affairs | Sale | 28.8K | $13.00 | $373.8K | SEC ↗ |
| Dec 15, 2021 | Andrew Combs | EVP, Head of Chemistry | Purchase | 8.0K | $11.86 | $94.9K | SEC ↗ |
| Nov 18, 2021 | Deborah Morosini | EVP, Chief of Clinical Affairs | Sale | 28.8K | $15.88 | $456.5K | SEC ↗ |
Showing the 25 most recent of 57 Form 4 filings for Prelude Therapeutics Inc.
Most active PRLD insiders
- David J Mauro10 filings
- Vaddi Krishna10 filings
- Deborah Morosini6 filings
- Peggy Scherle6 filings
- Christopher Pierce5 filings
Ask anything about PRLD insider activity
Use Trabud's AI agent to query Prelude Therapeutics Inc's Form 4 history in plain English — "Show me PRLD CEO purchases this year" or compare it against any other ticker.
Open the AI agentPRLD insider trading FAQ
Are Prelude Therapeutics Inc insiders buying or selling?
In the last 12 months, Prelude Therapeutics Inc insiders reported 2 open-market purchases ($25.0M) and 0 sales ($0) — net buying of $25.0M. Since September 2020, Trabud has recorded 57 Form 4 filings for PRLD: 29 buys ($113.6M) and 28 sells ($10.4M). Over the full record that is net buying of $103.2M.
How many insiders trade PRLD stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Prelude Therapeutics Inc. The most recent filing was accepted on Apr 23, 2026.
Where does Trabud get PRLD insider trading data?
All PRLD insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.